ONT Direct RNA Sequencing Accuracy: m6A and Pseudouridine Calling

At a glance:

• Key takeaways
• The Trustworthiness of ONT Direct RNA Sequencing: Can You Rely on m6A and Pseudouridine Detection?
• The Science Behind m6A and Pseudouridine: Why These Modifications Matter
• How ONT Direct RNA Sequencing Works for Modification Detection
• m6A and Pseudouridine Calling Accuracy: What the Data Shows
• Improving Accuracy: Best Practices for RNA Input and Library Preparation
• Challenges in m6A and Pseudouridine Calling: Common Pitfalls and How to Overcome Them
• Best Use Cases for m6A and Pseudouridine Detection Using ONT Direct RNA Sequencing
• FAQ: m6A and Pseudouridine Calling with ONT Direct RNA Sequencing

Can you trust ONT Direct RNA Sequencing for m6A detection and pseudouridine calling? Short answer: yes—if you treat it like a native, single‑molecule assay and hold it to auditable standards. With RNA004 chemistry, Dorado/Remora modified base models, and well‑designed controls, ONT Direct RNA Sequencing accuracy is strong enough to support confident m6A and selected pseudouridine (Ψ) findings. The key is disciplined workflow design: enforce coverage gates, use motif/context filters, and validate priority sites.

Key takeaways

• ONT Direct RNA Sequencing accuracy for modification detection improves with RNA004 plus Dorado/Remora and careful QC.
• Trust m6A detection when you combine adequate site coverage (aim ≥10–20×), conservative apparent modification proportion (≥10% as a heuristic), replicate concordance, and controls (IVT or KO).
• Pseudouridine calling is feasible but often benefits from orthogonal validation (e.g., LC‑MS/MS or HydraPsiSeq/BID‑Seq) for high‑stakes sites.
• Native, non‑amplified single‑molecule reads avoid cDNA and antibody‑enrichment biases, enabling isoform‑resolved context.
• Document model versions, thresholds, and controls for reproducibility and compliance audits.

The Trustworthiness of ONT Direct RNA Sequencing: Can You Rely on m6A and Pseudouridine Detection?

You can rely on ONT Direct RNA Sequencing for m6A and Ψ when you run modern chemistry (RNA004), select appropriate Dorado/Remora models, and embed controls. DRS reads native RNA directly—no reverse transcription, no PCR—so you preserve the original modification signal. That native, single‑molecule quality is the core reason many labs prefer DRS for modification detection. In contrast, cDNA workflows and antibody enrichment can introduce amplification bias, motif bias, or capture inefficiencies that distort stoichiometry and isoform context.

Practically, confidence comes from three pillars: (1) adequate per‑site coverage to stabilize probability estimates, (2) thresholding that reflects model behavior and biology (e.g., DRACH motif for m6A), and (3) controls/replicates to bound false discovery. When those are in place, ONT Direct RNA Sequencing accuracy is fit for purpose in m6A discovery, differential analysis, and targeted Ψ confirmation.

The Science Behind m6A and Pseudouridine: Why These Modifications Matter

m6A is the most abundant internal modification in eukaryotic mRNA, enriched in DRACH motifs and often near stop codons and 3′ UTRs. It influences splicing, translation, and stability—changing RNA life cycles in tissue‑specific ways. Pseudouridine (Ψ), an isomer of uridine, alters hydrogen bonding and local structure, and is prominent in rRNA and tRNA but is also reported in mRNA. Accurate calling matters because modification stoichiometry and location can reshape transcript fate, impact isoform usage, and signal disease pathways in oncology, neuroscience, and virology. If you call the wrong site—or misestimate the fraction—you may chase artifacts rather than biology.

How ONT Direct RNA Sequencing Works for Modification Detection

Direct RNA Sequencing measures ionic current across k‑mers as native RNA translocates through a nanopore. RNA004 introduces a new RNA‑specific reader pore and chemistry that improves per‑read accuracy and output. Dorado integrates modified base models (originating from Remora) to emit per‑read/per‑site modification tags for m6A (often constrained by DRACH) and Ψ, enabling downstream analysis at single‑molecule resolution.

Because DRS avoids reverse transcription and amplification, you minimize biases that can skew modification profiles in cDNA or antibody enrichment workflows. You also retain isoform structure, enabling calls in transcripts and splice variants that are difficult to reconstruct from short reads. For a deeper overview of principles and workflow, see the explanation of ONT DRS mechanics in the CD Genomics guide: ONT Direct RNA Sequencing principles and workflow analysis.

If you want a practical overview of modification calling concepts and tag interpretation, see DRS methylation/modification detection overview.

m6A and Pseudouridine Calling Accuracy: What the Data Shows

Official ONT materials describe RNA004 accuracy/output gains and the availability of Dorado/Remora modified base models for m6A and Ψ. The ONT announcement summarizes that the latest kit achieves higher accuracy and yield, and outlines modified‑base workflows supported by Dorado and EPI2ME. See the description in the latest Direct RNA Sequencing kit blog from Oxford Nanopore (2024) and the Chemistry Technical Document.

Peer‑reviewed studies from 2024–2025 reinforce biological specificity and practical gains. For m6A, METTL3 knockout systems show expected reductions of high‑probability m6A calls compared to wild‑type, with enrichment in DRACH motifs and characteristic transcript regions, supporting specificity in real biology, as described by Park et al. (2025). Comparative assessments indicate Dorado on RNA004 often improves recall and stoichiometry correlation relative to legacy pipelines or tools like m6Anet; for example, Zou et al. (2025) discuss model behavior on RNA004 datasets.

For pseudouridine, confidence typically increases with orthogonal validation. A Nucleic Acids Research study in 2025 integrated DRS/cDNA nanopore data with LC‑MS/MS and chemical mapping to assign Ψ sites in a thermophile, highlighting that stringent filters and multi‑method confirmation produce reliable sets; see pseudouridine and ribosome stability study (2025). STAR Protocols provide step‑by‑step Ψ DRS detection and differential analysis, albeit without universal thresholds; consult Ψ DRS protocols and the Ψ differential analysis guide.

In short: ONT Direct RNA Sequencing accuracy for m6A is solid when modern models and controls are used; Ψ detection is feasible, especially in rRNA/tRNA and targeted mRNA contexts, but high‑stakes calls should include orthogonal validation.

Improving Accuracy: Best Practices for RNA Input and Library Preparation

High‑quality input and disciplined prep drive accuracy.

• RNA integrity and quantity: Aim for intact RNA (RIN >8) and sufficient mass (commonly ≥1 µg total RNA per library; check the latest kit protocol). Use RNase‑free technique, validated quantitation (Qubit), and integrity assays (Bioanalyzer/TapeStation).
• SQK‑RNA004 protocol fidelity: Follow ligation steps and loading guidance precisely; chemistry/flowcell compatibility matters. Use the latest Dorado with appropriate modified‑base models and document versions.
• QC checkpoints post‑run: Track alignment rate (>80% is a useful sanity check), read length distributions, per‑site coverage, and motif‑aware enrichment (DRACH for m6A) relative to controls.

For practical guidance on signal handling and visualization, see DRS signal handling and visualization.

Challenges in m6A and Pseudouridine Calling: Common Pitfalls and How to Overcome Them

Common pitfalls include low per‑site coverage, overlapping or context‑confounded peaks, inconsistent detection across replicates, chemistry/model mismatches, and RNA degradation. Remedies are straightforward but require discipline:

• Raise per‑site coverage gates (≥20× minimally for confident discovery; escalate for stoichiometry estimation).
• Apply motif‑aware filters (e.g., DRACH for m6A) and separate analyses where co‑calling m6A/Ψ increases misclassification risk.
• Require replicate intersection and, for priority sites, use orthogonal confirmation (LC‑MS/MS, chemical mapping).
• Keep Dorado/Remora models in sync with chemistry (RNA004) and record versions in your reports.
• Improve RNA QC and handling to reduce 3′ bias and dropout.

Best Use Cases for m6A and Pseudouridine Detection Using ONT Direct RNA Sequencing

DRS excels when native context and isoform resolution matter:

• Oncology: Isoform‑resolved m6A landscapes in tumors and organoids; differential m6A quantification with KO or inhibitor controls to anchor specificity.
• Neuroscience: Brain tissue and single‑nucleus contexts where antibody enrichment struggles; DRS preserves native transcripts and non‑coding RNAs relevant to neural regulation.
• Virology: Viral RNAs with complex secondary structure; high‑coverage runs with stringent filters reveal robust modification patterns.

For broader technology context and applications, see Direct RNA Sequencing: technology, applications, and future.

Practical example: In pilot m6A mapping projects, a typical design includes one IVT unmodified control, one METTL3‑KO control, and two biological replicates per condition. We document model versions, set initial gates at ≥10–20× per site and ≥10% apparent modification proportion, and pre‑register priority loci for orthogonal confirmation. This keeps audits simple and decisions grounded.

FAQ: m6A and Pseudouridine Calling with ONT Direct RNA Sequencing

• What is the accuracy of m6A detection using ONT Direct RNA Sequencing?

  Accuracy is application‑dependent, but with RNA004 plus Dorado/Remora, confidence is strong when you enforce coverage gates (≥10–20×), motif/context filters (DRACH), controls (IVT or KO), and replicate consistency. For high‑stakes sites, add orthogonal validation.

• How do you prepare RNA for modification calling?

  Use intact RNA (RIN >8), sufficient input (often ≥1 µg total RNA), and RNase‑free workflow. Follow SQK‑RNA004 steps carefully, and basecall with the latest Dorado modified‑base models.

• Can pseudouridine be reliably detected with ONT?

  Yes, especially in rRNA/tRNA and targeted mRNA contexts. Reliability improves with stringent filters, high coverage, and orthogonal confirmation (LC‑MS/MS or chemical mapping) for priority calls.

• What are the limitations of ONT for modification detection?

  Low coverage and degraded RNA reduce confidence; co‑calling multiple modification types can induce misclassification; universal thresholds aren't standardized—use heuristics plus controls and replicates.

• How do you interpret modification calling results?

  Combine model probabilities with coverage gates and biological context (e.g., DRACH for m6A). Require replicate agreement and consider intersection across callers (Dorado, m6Anet) for high‑confidence sets; validate priority sites orthogonally.

Action: Start Your m6A and Pseudouridine Pilot Today

If you prefer to outsource a controlled pilot rather than run it in‑house, CD Genomics can support pilot design, control panels, basecalling pipeline setup, and auditable QC reporting to help you meet validation goals; learn more on the CD Genomics long‑read sequencing page.

Sources and further reading

• ONT kit and model overviews: Latest Direct RNA Sequencing kit enables higher accuracy and output; Chemistry Technical Document; EPI2ME wf‑basecalling.
• m6A specificity example: METTL3 knockout study (2025) shows reduction in high‑probability m6A calls and DRACH enrichment.
• Model comparisons on RNA004: Comparative evaluation of models on RNA004 datasets (2025) discusses Dorado vs m6Anet behavior.
• Pseudouridine multi‑method validation: NAR study on Ψ and ribosome stability (2025).

Poly(A) Tail Length Analysis

Full-Length Transcript Sequencing (Iso-Seq)

Nanopore Direct RNA Sequencing

Nanopore Full-Length cDNA Sequencing